DSIP: Delta Sleep-Inducing Peptide Benefits and Research (2026)
Searches for DSIP peptide benefits usually return a tidy list of promises: deeper sleep, less stress, faster recovery. The published record is thinner and older than the marketing suggests. DSIP (delta sleep-inducing peptide) was isolated in 1974, and after fifty years its own biological role is still described in the literature as unresolved.
The Compound Universe Take: DSIP is a nine-amino-acid neuropeptide first extracted from sleeping rabbits. A few small human infusions in the 1980s reported longer, more efficient sleep, and animal work points to stress-buffering, antioxidant, and pain-threshold effects. None of it amounts to proven human therapy, DSIP is not FDA-approved, and its link to sleep remains scientifically disputed.
New here? Start with the peptides researched for sleep overview for the full picture, then use this page for the compound itself.
What the DSIP peptide actually is
DSIP is a nonapeptide, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, with a molecular weight near 850 daltons [1]. Swiss researchers led by Schoenenberger and Monnier isolated it in 1974 from the cerebrospinal blood of rabbits in delta-wave sleep, which is where the name comes from [1][2].
One detail undercuts most product pages. The gene that would encode DSIP has never been identified, no receptor has been confirmed, and its half-life in blood is roughly 15 minutes [1][3]. It behaves less like a settled hormone and more like an open question.
The table below sets the compound in context before the mechanisms.
| Attribute | Detail | Evidence tier | Legal status (US) |
|---|---|---|---|
| Class | Endogenous nonapeptide (neuropeptide) | Established structure | Not FDA-approved |
| Most studied for | Sleep onset and efficiency | Human pilot (small) | Sold research-use-only |
| Also researched for | Stress, oxidative stress, pain threshold | Animal / in-vitro | Not a supplement |
| Discovery | Rabbit CSF, 1974 | Historical | No approved indication |
The DSIP peptide benefits reported in research
Sleep: the original and best-studied claim (human pilot)
The strongest human signal is also the oldest. In a double-blind crossover infusion in six healthy volunteers, DSIP at 25 nmol/kg increased total sleep time by about 59 percent within a 130-minute window versus placebo, with shorter sleep onset and better sleep efficiency on the following night (Human pilot) [4].
A separate open clinical trial in patients with chronic insomnia reported normalized sleep and improved daytime mood across a series of injections (Human pilot, uncontrolled) [5]. These are small, decades-old studies, not modern controlled trials.
The honesty problem sits in the reviews. A 2006 analysis in the Journal of Neurochemistry concluded that the link between DSIP and sleep was never firmly characterized, and proposed that a DSIP-like peptide, not DSIP itself, might explain some effects (Review) [3]. Contradictory results, including trials that found no correlation, are part of the record.
Stress and the HPA axis (animal)
Animal work frames DSIP as a stress-limiting factor. It has been reported to blunt reactivity of the hypothalamic-pituitary-adrenal axis and to shift several neurotransmitter systems (Animal) [2]. This is mechanistic and preclinical, not a demonstrated anti-stress therapy in people.
Antioxidant and metabolic signals (in-vitro / animal)
In isolated rat mitochondria, DSIP has been reported to improve the efficiency of oxidative phosphorylation, and animal studies describe reduced markers of lipid and protein oxidation in brain tissue (In-vitro / Animal) [2]. A mouse study also reported geroprotective outcomes, including lower tumor incidence and extended maximum lifespan (Animal) [1].
Analgesia and neuroprotection (animal)
Given directly into the brain in animals, DSIP has shown antinociceptive effects, meaning a raised pain threshold, and antiedematic effects in models of toxic brain swelling (Animal) [2][6]. Human confirmation of these uses does not exist.
How DSIP is thought to work
DSIP crosses the blood-brain barrier through a saturable, high-affinity transport mechanism rather than by passive diffusion [7]. Once central, proposed actions include modulation of NMDA-receptor signaling and inhibition of somatostatin release through a dopaminergic pathway (Animal / in-vitro) [1][8].
Because no receptor has been isolated, every mechanism here is a working hypothesis, not a mapped pathway.
Read this before the hype: DSIP is not FDA-approved and is sold for research use only. A preparation called Deltaran has seen clinical use in some Eastern European settings, but long-term safety has not been established in controlled research. This page summarizes published findings; it is not medical advice, a dosing guide, or an endorsement of use. Legal status varies by jurisdiction and is changing.
| Effect area | Proposed mechanism | Evidence maturity | Regulatory status |
|---|---|---|---|
| Sleep | Delta-wave promotion; BBB transport | Small human pilots, disputed | Not FDA-approved |
| Stress | HPA-axis modulation | Animal | Research-use-only |
| Oxidative stress | Improved oxidative phosphorylation | In-vitro / animal | Not a supplement |
| Pain | Central antinociception | Animal | No approved indication |
Key takeaways
- DSIP peptide benefits rest mainly on small human sleep pilots from the 1980s, not modern controlled trials [4].
- DSIP is a nine-amino-acid neuropeptide isolated from rabbit sleep in 1974, with no confirmed gene or receptor [1][3].
- The clearest human signal is faster, more efficient sleep after intravenous infusion, reported in a double-blind crossover of six volunteers [4].
- Stress-buffering, antioxidant, and analgesic effects come from animal and in-vitro work, tied to HPA-axis and mitochondrial signals [2].
- DSIP is not FDA-approved and is sold research-use-only, so every benefit here is research-stage, not established therapy.
Frequently asked questions
What are the main DSIP peptide benefits studied so far?
Research has looked at sleep efficiency, stress response, oxidative stress, and pain threshold. The sleep effect has the only human data, and even that comes from small pilots.
Does DSIP actually improve sleep?
Small human infusions reported longer, more efficient sleep, but later reviews found the DSIP-sleep link was never firmly established. The evidence is limited and partly contradictory.
Is DSIP FDA-approved?
No. DSIP has no approved indication in the United States and is sold for research use only. A preparation called Deltaran has been used clinically in some Eastern European countries.
How was DSIP discovered?
Swiss researchers isolated it in 1974 from the cerebrospinal blood of rabbits in delta-wave sleep, which is the origin of the name delta sleep-inducing peptide.
Is DSIP a hormone?
Its status is unclear. No gene, receptor, or precursor has been confirmed, so it is best described as an endogenous neuropeptide with an unresolved biological role.
Is DSIP safe?
Short human studies reported few side effects, but long-term safety has not been established in controlled trials. It remains an investigational research compound, not a validated treatment.
DSIP research sits where sleep neuroscience meets stress biology, since delta sleep-inducing peptide, the rabbit-derived nonapeptide that crosses the blood-brain barrier by saturable transport and appears to touch NMDA signaling, somatostatin release, and HPA-axis reactivity, has been tied to slow-wave sleep, oxidative phosphorylation in mitochondria, and antinociception across animal and small human studies; Compound Universe tracks the compound against the primary literature, including the Kovalzon riddle review and the Schneider-Helmert infusion trials, so the summary reflects evidence maturity rather than marketing.
DSIP peptide benefits make a useful case study in reading peptide research honestly: a real molecule with a genuine, half-century-old literature, a handful of promising human sleep pilots, a stack of animal mechanism papers, and a still-open scientific question about what it even does. For the wider picture, see a related compound studied for sleep and aging and the Compound Universe guide to peptide legality.
References
- Delta-sleep-inducing peptide. Structure, discovery (Schoenenberger and Monnier, 1974), pharmacokinetics, and geroprotective mouse data. Encyclopedic summary with primary citations.
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984. PMID 6145137.
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. PMID 16539679.
- Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981. PMID 6895513.
- A clinical trial with DSIP. (Open study, insomnia patients.) PMID 6391926.
- The effect of the delta sleep-inducing peptide on the development of toxic brain edema-swelling. PMID 1290809.
- Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain. PMID 2547200.
- Delta sleep inducing peptide inhibits somatostatin release via a dopaminergic mechanism. PMID 2886936.